50242-0245 Phesgo - CanMED: NDC

Product NDC:

50242-0245

Brand Name:

Phesgo

Generic Name:

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf

Dosage Form Name:

INJECTION, SOLUTION

Administration Route:

Subcutaneous

Substances:

Name: HYALURONIDASE (HUMAN RECOMBINANT)

Strength: 30000.0

Unit: U/15mL

Name: PERTUZUMAB

Strength: 1200.0

Unit: mg/15mL

Name: TRASTUZUMAB

Strength: 600.0

Unit: mg/15mL

Packages:

Code: 50242-0245-01

Description: 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-245-01) / 15 mL in 1 VIAL, SINGLE-DOSE

Effective Date: June 29, 2020

Discontinued:

Code: 50242-0245-86

Description: 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-245-86) / 15 mL in 1 VIAL, SINGLE-DOSE

Effective Date: May 3, 2021

Discontinued:

SEER*Rx Category:

Immunotherapy

Major Class:

Monoclonal Antibody

Minor Class:

HER2

Orphan Drug Designation:

Status:

In Use

CanMED and the Oncology Toolbox